Search results for "Antiparkinson Agent"

showing 4 items of 24 documents

Early DEtection of wEaring off in Parkinson disease: The DEEP study

2014

Assessing the frequency of Wearing-Off (WO) in Parkinson's disease (PD) patients, and its impact on Quality of Life (QoL). METHODS: Consecutive ambulatory patients, who were on dopaminergic treatment for ≥ 1 year, were included in this multicentre, observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as using the validated Italian version of a patient self-rated 19-question Wearing-Off Questionnaire (WOQ-19); WO was defined for scores ≥ 2. QoL was evaluated by the 8-item Parkinson's Disease Questionnaire (PDQ-8). RESULTS: 617 subjects were included, with a mean anti-Parkinson treatment duration of 6.6 ± 4.6 years, 87.2% were on lev…

QuestionnairesAdultMaleQuality of lifeLevodopamedicine.medical_specialtyPediatricsParkinson's diseaseTreatment durationParkinson's diseaseEarly detectionDiseaseLevodopaAntiparkinson AgentsQuality of lifeSurveys and Questionnairesmedicine80 and overHumansWearing-offAgedAged 80 and overParkinson's disease; Quality of life; Wearing-off; Wearing-off questionnairebusiness.industryParkinson DiseaseParkinson's disease; quality of life; wearing-off; wearing-off questionnaireMiddle Agedmedicine.diseaseLevodopa; Questionnaires; Parkinson's disease; Humans; Wearing-off; Quality of Life; Aged; Antiparkinson Agents; Cross-Sectional Studies; Wearing-off questionnaire; Parkinson Disease; Aged 80 and over; Adult; Middle Aged; Male; Female; Quality of lifeCross-Sectional StudiesNeurologyAmbulatoryPhysical therapyWearing-off questionnaireObservational studyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and Gerontologybusinessmedicine.drug
researchProduct

Melatonin levels in Parkinson's disease: Drug therapy versus electrical stimulation of the internal globus pallidus

1997

The objective of our work was to measure plasma melatonin levels in patients with Parkinson's Disease (PD) following electrical stimulation of the internal globus pallidus (GPi), and to compare these levels with groups of PD patients under drug therapy and healthy controls. The levels of melatonin were measured twice daily at 1000 and 1200. The GPi stimulation at 130 Hz lowered melatonin levels, while no changes were observed in the absence of stimulation. The melatonin levels from healthy subjects were lower than those observed in PD patients. The melatonin levels from PD patients under drug therapy were also measured during the night (2000-2400-0400) and at 0800 in order to observe their …

endocrine systemAgingmedicine.medical_specialtyParkinson's diseaseElectric Stimulation TherapyStimulationGlobus PallidusBiochemistryAntiparkinson AgentsMelatoninEndocrinologyPharmacotherapyInternal medicineGeneticsmedicineHumansIn patientCircadian rhythmMolecular BiologyMelatoninInternal globus pallidusbusiness.industryParkinson DiseaseCell Biologymedicine.diseaseCircadian RhythmEndocrinologyGlobus pallidusbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental Gerontology
researchProduct

Memory for time intervals is impaired in left hemi-Parkinson patients.

2004

The basal ganglia have been proposed as one of the neural correlates of timekeeping functions. Both encoding and memory retrieval components for time perception are impaired in Parkinson's disease (PD). The aim of our study was to investigate in hemi-Parkinsonian patients the existence of a specific alteration in memory for time depending on the affected side, to better understand the contribution of the left or right basal ganglia circuits in different components of time perception. Right and left hemi-PD patients performed a time reproduction task in which they were required to reproduce in the same session short (5 s) and long (15 s) time intervals, in off- and on-therapy condition. Whil…

endocrine systemmedicine.medical_specialtyParkinson's diseaseTime FactorsParkinson's diseaseCognitive NeuroscienceHemi-Parkinsonian patientsTime perceptionTime perception Parkinson's disease Memory Migration effect Cognitive functions Hemi-Parkinsonian patients Basal gangliaExperimental and Cognitive PsychologyAudiologyFunctional LateralityNOAntiparkinson AgentsLevodopaBehavioral NeuroscienceMemoryBasal gangliaTask Performance and AnalysismedicineHumansLevodopa; Analysis of Variance; Parkinson Disease; Humans; Task Performance and Analysis; Antiparkinson Agents; Aged; Middle Aged; Time Factors; Memory Disorders; Functional Laterality; FemaleMemory disorderAgedNeural correlates of consciousnessAnalysis of VarianceMemory DisordersSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaMemoriaCognitive disorderCognitionParkinson DiseaseBasal ganglia; Cognitive functions; Hemi-Parkinsonian patients; Memory; Migration effect; Parkinson's disease; Time perception;Time perceptionMiddle Agedmedicine.diseaseCognitive functionsBasal gangliaSettore MED/26 - NeurologiaMigration effectFemalePsychologyNeuroscienceNeuropsychologia
researchProduct

Practical importance of neuroprotection in Parkinson's disease.

2003

Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeu…

medicine.medical_specialtyNeurologyParkinson's diseaseIndolesBioinformaticsNeuroprotectionAntiparkinson AgentsDegenerative diseaseSelegilineAmantadineMedicineHumansbusiness.industrySelegilineAmantadineParkinson Diseasemedicine.diseaseClinical trialRopiniroleNeuroprotective AgentsNeurologyDopamine AgonistsNeurology (clinical)businessNeurosciencemedicine.drugJournal of neurology
researchProduct